You are here

New therapeutic approaches to identifying molecules for opioid abuse treatment

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DA055419-01
Agency Tracking Number: R43DA055419
Amount: $256,220.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDA
Solicitation Number: DA19-019
Timeline
Solicitation Year: 2019
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-04-15
Award End Date (Contract End Date): 2023-04-14
Small Business Information
5616 HILLTOP NEEDMORE RD
Fuquay Varina, NC 27526-9278
United States
DUNS: 079704473
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 SEAN EKINS
 (215) 687-1320
 sean@collaborationspharma.com
Business Contact
 SEAN EKINS
Phone: (215) 687-1320
Email: sean@collaborationspharma.com
Research Institution
N/A
Abstract

Project Summary
Collaborations Pharmaceuticals Inc. is a small business focused on developing treatments for difficult to treat
diseases. The ongoing overreliance on opioids for chronic pain despite their poor ability to improve function has
contributed to a significant and alarming epidemic of opioid overdose deaths and addictions in recent years.
Despite the overwhelming addiction crisis, few therapies exist, and with low efficacy. Thus, a critical unmet need
is an effective and safe treatment for opioid abuse disorders. Recent research has suggested that psychedelics
are also capable of reducing drug-dependence, including opioid abuse, and that serious adverse effects are
extremely rare. This drug abuse cessation is linked to the induction of neuritogenesis and increased
neuroplasticity, a hallmark of psychedelics. While the psychedelic experience and neuroplasticity induction
appear interlinked, several analogs of psychedelics have been proposed which induce neuroplasticity and drug-
avoidance while seemingly lacking the psychedelic experience. Although few in number, these analogs have
been named “psychoplastogens” and are promising candidates for treatment of opioid drug abuse. The de-
coupling of the psychedelic experience and neuroplasticity induction is linked to receptor specificity as
psychoplastogens are specific to 5HT2A. Here, we propose to use a combination of generative machine learning
models with our extensive experience of supervised machine models to generate new analogs of psychedelics
that will have improved 5-HT2A specificity, ADME properties, and are easily synthesizable to rapidly expand the
pool of known psychoplastogens, significantly increasing potential therapeutic options for opioid abuse
treatment.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government